Mode
Text Size
Log in / Sign up
Phase 1 N=7 Treatment

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Enrolled (actual)
7
Serious AEs
28.6%
Results posted
Nov 2022
Primary outcome: Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Tazemetostat (Drug)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Eisai Co., Ltd.
Primary completion
Jul 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Dose-limiting Toxicities (DLTs)
SECONDARY
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
7; 2
SECONDARY
Cmax: Maximum Plasma Concentration of Tazemetostat and Its Metabolite ER-897387
988; 790
SECONDARY
Tmax: Time to Reach Maximum Plasma Concentration (Cmax) of Tazemetostat and Its Metabolite ER-897387
1.97; 1.97
SECONDARY
AUC(0-12 Hours): Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose of Tazemetostat and Its Metabolite ER-897387
4080; 4500
SECONDARY
AUC(0-t Hours): Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Tazemetostat and Its Metabolite ER-897387
5180; 6540
SECONDARY
AUC(0-infinity): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity of Tazemetostat and Its Metabolite ER-897387
5220; 6570
SECONDARY
Lambda z: Terminal Phase Elimination Rate Constant of Tazemetostat and Its Metabolite ER-897387
0.0925; 0.0794
SECONDARY
T1/2: Terminal Half-life of Tazemetostat and Its Metabolite ER-897387
7.76; 4.10; 8.68; 3.55
SECONDARY
CL/F: Apparent Total Body Clearance of Tazemetostat
153
SECONDARY
Vz/F: Apparent Volume of Distribution at Terminal Phase of Tazemetostat
1660; 1170
SECONDARY
MRT: Mean Residence Time of Tazemetostat and Its Metabolite ER-897387
8.25; 10.7
SECONDARY
AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval of Tazemetostat and Its Metabolite ER-897387
4220; 10200
SECONDARY
Css,Av: Average Steady State Plasma Concentration of Tazemetostat and Its Metabolite ER-897387
351; 852
SECONDARY
Css,Max: Maximum Steady State Plasma Concentration of Tazemetostat and Its Metabolite ER-897387
1170; 1800
SECONDARY
Css,Min: Minimum Steady State Plasma Concentration of Tazemetostat and Its Metabolite ER-897387
88.4; 293
SECONDARY
PTF: Peak-trough Fluctuation Ratio of Tazemetostat and Its Metabolite ER-897387
303; 171
SECONDARY
Tss,Max: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State of Tazemetostat and Its Metabolite ER-897387
1.05; 1.07
SECONDARY
CLss/F: Apparent Total Body Clearance of Tazemetostat at Steady State
190
SECONDARY
Rac (Cmax): Accumulation Ratio of Cmax for Tazemetostat and Its Metabolite ER-897387
1.19; 2.28
SECONDARY
Rac (AUC): Accumulation Ratio of AUC for Tazemetostat and Its Metabolite ER-897387
1.04; 2.27
SECONDARY
Rss: Steady State Accumulation Ratio of Tazemetostat and Its Metabolite ER-897387
0.809; 1.56
SECONDARY
Ae: Amount of Unchanged Drug Tazemetostat Excreted in Urine
15.1; 6.81
SECONDARY
Fe: Fraction of Tazemetostat Dose Excreted in Urine
1.89; 0.852
SECONDARY
CLR: Renal Clearance of Tazemetostat
2.62; 1.62
SECONDARY
Percentage of Participants With Objective Response
57.1

Summary

This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

Eligibility Criteria

Inclusion Criteria

  • Participants with histological diagnosis of B-cell non-Hodgkin's lymphoma
  • Participant who has measurable disease
  • Participant who had previous therapy with systemic chemotherapy and/or antibody therapy
  • Participant who had progressive disease (PD) or did not have a response (complete response [CR] or partial response [PR]) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
  • Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participant with life expectancy of ≥3 months from starting study drug administration
  • Participant with adequate renal, bone marrow, and liver function
  • Participant with left ventricular ejection fraction (LVEF) > 50%
  • Male and female participant ≥20 years of age at the time of informed consent
  • Participant who has provided written consent to participate in the study

Exclusion Criteria

  • Participant with prior exposure to EZH2 inhibitor
  • Participant with a history or a presence of central nerves invasion
  • Participant with allogeneic stem cell transplantation
  • Participant with medical need for the continued use of potent or moderate inhibitors of CYP3A or P-gp, or potent or moderate inducer of CYP3A (including St. John's wort).
  • Participant with significant cardiovascular impairment
  • Participant with prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 480 milliseconds (msec)
  • Participant with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug
  • Participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis
  • Participant with active infection requiring systemic therapy
  • Women of childbearing potential or man of impregnate potential who don't agree to use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later from last administration of study drug
  • Woman who are pregnant or breastfeeding
  • Participant who were deemed as inappropriate to participate in the study by the investigator or sub-investigator
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03009344). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search